FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and …
Post
-
-
The future of third-party logistics in an evolving biopharmaceutical world
Despite inflationary pressures and ongoing challenges in the geopolitical landscape, expectations are high regarding the biopharmaceutical industry’s growth prospects. A …
-
Reprieve for WuXi as Biosecure vote likely pushed to 2025
The Biosecure Act was left out of a key US defence bill that passed in the House this week, in …
-
Small cell lung cancer: Navigating the global clinical trial landscape
Small cell lung cancer is a fast-growing and aggressive subtype of lung cancer, accounting for approximately 10-15% of all lung …
-
EMA recommends expanding approval of Ofev to children and adolescents
Boehringer Ingelheim has won a positive European Medicines Agency (EMA) recommendation for blockbuster Ofev’s (nintedanib) use in children and adolescents …
-
Denmark’s HTA evolution
New health technology assessment (HTA) statistics produced by Denmark’s Medicine Council (Medicinrådet) for 2024 have prompted GlobalData to take the …
-
EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for …
-
AbbVie to acquire Nimble Therapeutics for $200m
AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim …
-
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders. According to …
-
Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?
Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19). According …
-
Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-6234?
AZD-6234 is a synthetic peptide commercialized by AstraZeneca, with a leading Phase I program in Obesity. According to Globaldata, it …
-
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s RYZ-101?
RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). …
-
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sipavibart?
Sipavibart is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19). According …
-
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Eloralintide?
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity. According …
-
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, …